Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.